Fundraising Fox

KPI Therapeutics

Seattle, US · Founded 2013 · Delaware corporation

Biotech

Founders & leadership

CL
Charles L. MagnessExecutive
ML
Magness L. CharlesExecutive

Reported raises · per SEC filings

Form D private placements

$1.7M disclosed across 4 rounds · 2014–2016

▶$18KraisedDec 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shawn IadonatoDirector
  • James G. W. ReedDirector
  • Ray BartoszekDirector
  • Craig PhilipsExecutive Officer
  • Paul SylvesterDirector
  • Charles L. MagnessExecutive Officer, Director
  • Steven MitchelDirector
  • Don MerlinoDirector
  • Thomas E HornishExecutive Officer
Offering amount
$3M
Amount sold
$18K
Minimum investment
$50K
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50.5KraisedFeb 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Don MerlinoDirector
  • James G. W. ReedDirector
  • Craig PhilipsExecutive Officer
  • Blake IlstrupExecutive Officer
  • Charles L. MagnessExecutive Officer, Director
  • Paul SylvesterDirector
Offering amount
$7.5M
Amount sold
$50.5K
Minimum investment
$50K
First sale
Feb 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$27KraisedMay 2015 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles L. MagnessExecutive Officer, Director
Offering amount
$7M
Amount sold
$27K
Minimum investment
$10K
First sale
May 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedMay 2014 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Magness L. CharlesExecutive Officer, Director
Offering amount
$10M
Amount sold
$1.6M
Minimum investment
$25K
First sale
May 2014
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

KPI Therapeutics Announces Expanded Drug Programs In Eye And Skin Diseases - BioSpacebiospace.com · Feb 2016Biotech Consortium Launches KPI Therapeutics, Inc., a New Collaborative Initiative to Speed Drug Development and Improve Investor Outcomes | Fierce Biotechfiercebiotech.com · Jun 2014Five Biotechs, Private Investors Launch KPI Therapeutics - BioSpacebiospace.com · Jun 2014

Frequently asked questions

How much funding has KPI Therapeutics raised?
KPI Therapeutics has disclosed $1.7M raised across 4 rounds.
Where is KPI Therapeutics headquartered?
KPI Therapeutics is headquartered in Seattle, US.